<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338427</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 063-14</org_study_id>
    <nct_id>NCT02338427</nct_id>
  </id_info>
  <brief_title>Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis</brief_title>
  <acronym>IPA</acronym>
  <official_title>Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis. Multicenter Prospective</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyloidosis is involved in many rare diseases in relation to the diversity of amyloid
      proteins involved in the formation of abnormal tissue deposits. There are approximately 30
      proteins involved in amylose's constitution. The therapeutic management varies depending on
      the type of amyloidosis observed.

      The application of conventional techniques immunolabeling of amylose does not allow the
      comprehensive characterization of amylose forms, due to failures of the technic, the false
      positivity of some results, or lack of frozen tissue available for typing light chain
      (lambda, kappa).

      In this study, the main objective is the comparison of two capacity of amylose
      characterisation: immunohistochemistry and proteomics analysis.

      The purpose of this study is to validate the superiority of proteomic analysis by
      demonstrating the improvement of the precision, the reduction of technical failure, as well
      as the correction of erroneous diagnosis, authorizing a more adapted therapeutic management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification success of amylose by immunohistochemistry and proteomic analysis</measure>
    <time_frame>Inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>proteomic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunohistochemistry</intervention_name>
    <arm_group_label>proteomic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Proteomic analysis</intervention_name>
    <arm_group_label>proteomic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Upper age to 18 years

          -  Amylose diagnosis establish by tissue sample, after &quot;Rouge Congo&quot; coloration

          -  All patient with amylose identified by the two laboratory of anatomopathology

          -  Sample necessary for realized proteomic analysis

          -  No opposition at the participation of the study

          -  Patient sign an informed consent for biology collection

        Exclusion Criteria:

          -  Tissue sample inadequate for apply immunohistochemistry or proteomic identification

          -  Patient trust, guardianship, under legal protection measure, deprived of freedom
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé MAISONNEUVE, PH</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Départementel Vendée</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucie AUZANNEAU</last_name>
    <phone>02 51 44 63 80</phone>
    <email>lucie.auzanneau@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Vendee</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hervé MAISONNEUVE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe MOREAU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

